Amantadine hydrochloride monitoring by dried plasma spot technique: High-performance liquid chromatography-tandem mass spectrometry based clinical assay
Li et al.
The finding, in our words
A dried plasma spot assay for amantadine was developed and validated across a haematocrit range of 20–50% with linearity 100–2000 ng/mL and stability for 21 days at room temperature; in 52 patients, dried plasma spots showed strong agreement with wet plasma by Deming regression and Bland–Altman analysis, supporting decentralised therapeutic drug monitoring with patient self-sampling.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
In lung and renal transplant recipients, VAMS sampling with LC-MS/MS quantification of mycophenolic acid and tacrolimus showed good linearity and accuracy, and with a haematocrit-adjusted conversion formula achieved clinical agreement in most samples; tacrolimus did not require haematocrit correction. The approach is virtually painless and enables richer sampling for more accurate drug exposure estimates, supporting decentralised therapeutic drug monitoring.
Juan et al., Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · source ↗
This study validated a method for monitoring mycophenolic acid in paediatric patients, demonstrating that quantitative dried plasma spots achieved close agreement with venous plasma. Quantitative dried blood spots showed significant haematocrit-related bias, making the plasma-based format more suitable for decentralised monitoring.
Kocur et al., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (paywalled) · source ↗
Volumetric microsampling can enable patient-centred therapeutic drug monitoring with high patient preference and acceptable method validation for many drugs, but conversion from capillary to plasma and agreement with venous sampling varies by analyte and requires careful validation.
Tummala et al., Journal of clinical pharmacology (paywalled) · source ↗
The study validated an LC-MS/MS method for eight antiepileptic drugs and two metabolites in dried blood spot and VAMS formats, with satisfactory analytical performance and stability, and was the first to include the oxcarbazepine metabolite DHCB. In 80 paired patient samples, microsampling concentrations showed promising correlation with plasma, supporting decentralised therapeutic drug monitoring of antiepileptic treatment.
Cobo-Golpe et al., Journal of analytical toxicology · source ↗